SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-18-011649
Filing Date
2018-08-14
Accepted
2018-08-14 10:11:35
Documents
68
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 652739
2 ex31-1.htm EX-31.1 19249
3 ex31-2.htm EX-31.2 18385
4 ex32-1.htm EX-32.1 10037
  Complete submission text file 0001493152-18-011649.txt   4093026

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE imun-20180630.xml EX-101.INS 731956
6 XBRL SCHEMA FILE imun-20180630.xsd EX-101.SCH 58256
7 XBRL CALCULATION FILE imun-20180630_cal.xml EX-101.CAL 61800
8 XBRL DEFINITION FILE imun-20180630_def.xml EX-101.DEF 163832
9 XBRL LABEL FILE imun-20180630_lab.xml EX-101.LAB 332895
10 XBRL PRESENTATION FILE imun-20180630_pre.xml EX-101.PRE 262118
Mailing Address 37 NORTH ORANGE AVENUE SUITE 607 ORLANDO FL 32801
Business Address 37 NORTH ORANGE AVENUE SUITE 607 ORLANDO FL 32801 (888) 613-8802
Immune Therapeutics, Inc. (Filer) CIK: 0001559356 (see all company filings)

IRS No.: 593226705 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-54933 | Film No.: 181014947
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1